TP53-mut AML — chemo-resistant, dismal outcomes (CR ~20% with 7+3, OS ~6 mo). Decitabine...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-AML |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AML |
| Sources | SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-AML |
| ESCAT tier | IIIB |
| Recommended combinations | azacitidine + venetoclax (palliative, R/R), decitabine 10-day, alloSCT consideration, clinical trial |
| Evidence summary | TP53-mut AML — chemo-resistant, dismal outcomes (CR ~20% with 7+3, OS ~6 mo). Decitabine 10-day or azacitidine + venetoclax (CR ~50% but non-durable in TP53-mut). AlloSCT outcomes poor but still preferred when feasible. |
Notes
ESCAT IIIB. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.